These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37740609)

  • 21. Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies.
    Roth JA; Gulati R; Gore JL; Cooperberg MR; Etzioni R
    JAMA Oncol; 2016 Jul; 2(7):890-8. PubMed ID: 27010943
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incorporating Biomarkers into the Primary Prostate Biopsy Setting: A Cost-Effectiveness Analysis.
    Sathianathen NJ; Kuntz KM; Alarid-Escudero F; Lawrentschuk NL; Bolton DM; Murphy DG; Weight CJ; Konety BR
    J Urol; 2018 Dec; 200(6):1215-1220. PubMed ID: 29906434
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.
    Brown LC; Ahmed HU; Faria R; El-Shater Bosaily A; Gabe R; Kaplan RS; Parmar M; Collaco-Moraes Y; Ward K; Hindley RG; Freeman A; Kirkham A; Oldroyd R; Parker C; Bott S; Burns-Cox N; Dudderidge T; Ghei M; Henderson A; Persad R; Rosario DJ; Shergill I; Winkler M; Soares M; Spackman E; Sculpher M; Emberton M
    Health Technol Assess; 2018 Jul; 22(39):1-176. PubMed ID: 30040065
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of percent free PSA for prostate cancer detection in men with a total PSA of 4-10 ng/ml.
    Bermúdez-Tamayo C; Martín Martín JJ; González Mdel P; Pérez Romero C
    Urol Int; 2007; 79(4):336-44. PubMed ID: 18025853
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The prostate: decreasing cost-effectiveness of biopsy with advancing age.
    Gottlieb RH; Mooney C; Mushlin AI; Rubens DJ; Fultz PJ
    Invest Radiol; 1996 Feb; 31(2):84-90. PubMed ID: 8750443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost effectiveness of risk-prediction tools in selecting patients for immediate post-prostatectomy treatment.
    Zubek VB; Konski A
    Mol Diagn Ther; 2009; 13(1):31-47. PubMed ID: 19351214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic Review of Cost-Effectiveness Models in Prostate Cancer: Exploring New Developments in Testing and Diagnosis.
    Keeney E; Thom H; Turner E; Martin RM; Morley J; Sanghera S
    Value Health; 2022 Jan; 25(1):133-146. PubMed ID: 35031092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation.
    Sharma P; Boyers D; Boachie C; Stewart F; Miedzybrodzka Z; Simpson W; Kilonzo M; McNamee P; Mowatt G
    Health Technol Assess; 2012; 16(17):1-266. PubMed ID: 22469073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada.
    Pataky R; Gulati R; Etzioni R; Black P; Chi KN; Coldman AJ; Pickles T; Tyldesley S; Peacock S
    Int J Cancer; 2014 Aug; 135(4):939-47. PubMed ID: 24443367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-Effectiveness Analysis of Stockholm 3 Testing Compared to PSA as the Primary Blood Test in the Prostate Cancer Diagnostic Pathway: A Decision Tree Approach.
    Risør BW; Tayyari Dehbarez N; Fredsøe J; Sørensen KD; Pedersen BG
    Appl Health Econ Health Policy; 2022 Nov; 20(6):867-880. PubMed ID: 35934771
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.
    Tawfik A
    Ont Health Technol Assess Ser; 2015; 15(11):1-37. PubMed ID: 26366237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Benefit, Harm, and Cost-effectiveness Associated With Magnetic Resonance Imaging Before Biopsy in Age-based and Risk-stratified Screening for Prostate Cancer.
    Callender T; Emberton M; Morris S; Pharoah PDP; Pashayan N
    JAMA Netw Open; 2021 Mar; 4(3):e2037657. PubMed ID: 33704474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screening.
    Ellison L; Cheli CD; Bright S; Veltri RW; Partin AW
    Urology; 2002 Oct; 60(4 Suppl 1):42-6. PubMed ID: 12384162
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Active Surveillance Strategies for Low-Grade Prostate Cancer: Comparative Benefits and Cost-effectiveness.
    Kang SK; Mali RD; Prabhu V; Ferket BS; Loeb S
    Radiology; 2021 Sep; 300(3):594-604. PubMed ID: 34254851
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic evaluation of diagnostic localization following biochemical prostate cancer recurrence.
    Barocas DA; Bensink ME; Berry K; Musa Z; Bodnar C; Dann R; Ramsey SD
    Int J Technol Assess Health Care; 2014 Oct; 30(4):345-53. PubMed ID: 25399914
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Focal therapy versus radical prostatectomy and external beam radiotherapy as primary treatment options for non-metastatic prostate cancer: results of a cost-effectiveness analysis.
    Reddy D; van Son M; Peters M; Bertoncelli Tanaka M; Dudderidge T; Cullen E; Ho CLT; Hindley RG; Emara A; McCracken S; Orczyk C; Shergill I; Mangar S; Nigam R; Virdi J; Moore CM; Arya M; Shah TT; Winkler M; Emberton M; Falconer A; Belsey J; Ahmed HU
    J Med Econ; 2023; 26(1):1099-1107. PubMed ID: 37656223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate cancer screening in Tyrol, Austria: experience and results.
    Horninger W; Reissigl A; Rogatsch H; Volgger H; Studen M; Klocker H; Bartsch G
    Eur Urol; 1999; 35(5-6):523-38. PubMed ID: 10325519
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-Effectiveness Analysis of Prostate Cancer Screening in Brazil.
    Oliveira RAR; Mourão TC; Santana TBM; Favaretto RL; Zequi SC; Guimarães GC
    Value Health Reg Issues; 2021 Dec; 26():89-97. PubMed ID: 34146776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-Effectiveness of Urinary Biomarker Panel in Prostate Cancer Risk Assessment.
    Govers TM; Caba L; Resnick MJ
    J Urol; 2018 Dec; 200(6):1221-1226. PubMed ID: 30012363
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.